{
    "clinical_study": {
        "@rank": "126076", 
        "arm_group": {
            "arm_group_label": "Rectiv", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "RECTIV\u00ae is an ointment containing 0.4% nitroglycerin (NTG) for the treatment of moderate to\n      severe pain associated with chronic anal fissure approved in June 2011 by the US Food and\n      Drug Administration (FDA) for adults. The purpose of this study is to assess the safety,\n      pharmacokinetics, and exploratory efficacy of RECTIV\u00ae in adolescents"
        }, 
        "brief_title": "Pharmacokinetic,Safety and Exploratory Efficacy of RECTIV\u00ae in Adolescents With Chronic Anal Fissure", 
        "completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Anal Fissure", 
        "condition_browse": {
            "mesh_term": "Fissure in Ano"
        }, 
        "detailed_description": {
            "textblock": "This is an open-label, multicenter study conducted in up to 10 sites in the United States.\n      A total of 13 pediatric male or female patients age \u226512 to <17 years will be enrolled. The\n      patients will administer a dose of Rectiv\u00ae  twice daily to characterize the safety,\n      pharmacokinetics , and exploratory efficacy of Nitroglycerin Ointment 0.4% (RECTIV\u00ae )over 5\n      days"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Key Inclusion Criteria:\n\n          -  Male or female \u226512 and <17 years of age\n\n          -  At least 1 anal fissure for a minimum of 3 weeks in duration\n\n          -  Anal fissure pain experienced over the last 24 hours at Screening and before\n             enrollment\n\n          -  Patient (and parent or caregiver as appropriate) has provided written  informed\n             consent\n\n        Key Exclusion Criteria:\n\n          -  Current diagnosis of hemorrhoids\n\n          -  Hypersensitivity, allergy, or contraindication to nitroglycerin\n\n          -  History of hypertension and/or cardiovascular disease\n\n          -  History or current diagnosis of inflammatory bowel disease\n\n          -  History or current diagnosis of fistula(e)-in-ano or an anal abscess\n\n          -  Fibrotic anal stenosis\n\n          -  Previous anal surgery\n\n          -  Diagnosis of cancer\n\n          -  History of migraine or chronic headaches requiring treatment with analgesics\n\n          -  Pregnant or lactating female patients\n\n          -  Weight <36 kg"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "16 Years", 
            "minimum_age": "12 Years"
        }, 
        "enrollment": {
            "#text": "13", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 7, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01920074", 
            "org_study_id": "APT-NIT_S-PRO-M_PEDKPK1_E"
        }, 
        "intervention": {
            "arm_group_label": "Rectiv", 
            "intervention_name": "Nitroglycerin Ointment 0.4%", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Nitroglycerin"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Anal Fissure", 
            "Nitroglycerin", 
            "Pediatrics", 
            "RECTIV\u00ae", 
            "Pediatric Research Equity Act"
        ], 
        "lastchanged_date": "August 16, 2013", 
        "location": [
            {
                "contact": {
                    "email": "rharb@chla.usc.edu", 
                    "last_name": "Rula Harb, MD", 
                    "phone": "323-361-4956"
                }, 
                "contact_backup": {
                    "email": "thernandez@chla.usc.edu", 
                    "last_name": "Tatiana Hernandez", 
                    "phone": "323.361.8631"
                }, 
                "facility": {
                    "address": {
                        "city": "Los Angeles", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "90027"
                    }, 
                    "name": "Children's Hospital"
                }, 
                "investigator": [
                    {
                        "last_name": "Hillel Naon, MD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Rula Harb, MD", 
                        "role": "Principal Investigator"
                    }
                ], 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "advancemrc@gmail.com", 
                    "last_name": "Rafael A Garcia, MD", 
                    "phone": "786-360-4423"
                }, 
                "contact_backup": {
                    "email": "advancemrc@gmail.com", 
                    "last_name": "Ana Acosta", 
                    "phone": "786-360-4423"
                }, 
                "facility": {
                    "address": {
                        "city": "Miami", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33135"
                    }, 
                    "name": "Advanced Medical Research Center"
                }, 
                "investigator": [
                    {
                        "last_name": "Rafael A Garcia, MD", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Aldo V Fonticiella, MD", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "devendra.mehta@orlandohealth.com", 
                    "last_name": "Devendra Mehta, MD", 
                    "phone": "321-841-6350"
                }, 
                "contact_backup": {
                    "email": "sarah.logie@orlandohealth.com", 
                    "last_name": "Sarah Logie", 
                    "phone": "321-841-6350"
                }, 
                "facility": {
                    "address": {
                        "city": "Orlando", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "32806"
                    }, 
                    "name": "Arnold Palmer Hospital for Children"
                }, 
                "investigator": [
                    {
                        "last_name": "Devendra Mehta, MD", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Jeffery Bornstien, MD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Reinaldo Figueroa-Colon, MD", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "phyman@lsuhsc.edu", 
                    "last_name": "Paul Hyman, MD", 
                    "phone": "504-896-9534"
                }, 
                "facility": {
                    "address": {
                        "city": "New Orleans", 
                        "country": "United States", 
                        "state": "Louisiana", 
                        "zip": "70118"
                    }, 
                    "name": "Children's Hospital"
                }, 
                "investigator": {
                    "last_name": "Paul Hyman, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sealy", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "77474"
                    }, 
                    "name": "Sealy Urgent Care Center and Medical Clinic"
                }, 
                "status": "Active, not recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase 4, Multiple-dose, Pharmacokinetic, Safety, and Exploratory Efficacy Study of Nitroglycerin Ointment 0.4% (RECTIV\u00ae) in Adolescents (Age \u226512 to <17 Years) With Moderate to Severe Pain Due to Chronic Anal Fissure", 
        "other_outcome": {
            "description": "Safety and tolerability are assessed through AEs, clinical laboratory test results (hematology, serum biochemistry, and urinalysis), vital sign measurements (heart rate, supine and orthostatic blood pressure, oral temperature, and respiratory rate), 12-lead ECG results, anal area assessment, physical examination findings (including body weight), and concomitant medications (including the use of rescue acetaminophen for headaches).", 
            "measure": "To assess the safety of Rectiv\u00ae in adolescents (age \u226512 to <17 years)", 
            "safety_issue": "No", 
            "time_frame": "Screening through the completion of study participation"
        }, 
        "overall_contact": {
            "email": "ccharles@aptalispharma.com", 
            "last_name": "Carla M. Charles, MBS", 
            "phone": "908-927-9600", 
            "phone_ext": "4075"
        }, 
        "overall_official": [
            {
                "affiliation": "Aptalis Pharma, Bridgewater, NJ", 
                "last_name": "Gina Eagle, MD", 
                "role": "Study Director"
            }, 
            {
                "affiliation": "Children's Hospital, New Orleans, LA", 
                "last_name": "Paul Hyman, MD", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The following PK parameters will be calculated as data permit:\nMaximum observed concentration (Cmax)\nTime of the maximum observed plasma concentration (Tmax)\nArea under the concentration time curve from dosing up to the last quantifiable concentration (AUC0-last).\nArea under the concentration time curve from dosing up to 480 minutes (AUC0-480)\nThe extrapolated area under the concentration time curve from dosing up to 12 hours (AUC0-12h) also will be calculated if quantifiable concentrations are observed during the entire dose interval.\nTerminal elimination half-life (t1/2) On the basis of the results of the study, additional noncompartmental PK parameters may be calculated and reported.\nIn addition, a population PK model for NTG will be developed based on the PK data from Day 5.  By using this model, the following additional PK parameters may be reported:\nApparent volume of distribution (V/F)\nApparent clearance (CL/F)", 
            "measure": "Noncompartmental pharmacokinetic analyses will be performed on the full pharmacokinetic curves for NTG and its metabolites (1,2 glyceryl dinitrate and 1,3 glyceryl dinitrate) on Day 5", 
            "safety_issue": "No", 
            "time_frame": "Day 5"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01920074"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "results_reference": [
            {
                "PMID": "15949202", 
                "citation": "Demirbag S, Tander B, Atabek C, Surer I, Ozt\u00fcrk H, Cetinkursun S. Long-term results of topical glyceryl trinitrate ointment in children with anal fissure. Ann Trop Paediatr. 2005 Jun;25(2):135-7."
            }, 
            {
                "PMID": "11668104", 
                "citation": "Kenny SE, Irvine T, Driver CP, Nunn AT, Losty PD, Jones MO, Turnock RR, Lamont GL, Lloyd DA. Double blind randomised controlled trial of topical glyceryl trinitrate in anal fissure. Arch Dis Child. 2001 Nov;85(5):404-7."
            }, 
            {
                "PMID": "17096178", 
                "citation": "Schiano di Visconte M, Di Bella R, Munegato G. Randomized, prospective trial comparing 0.25 percent glycerin trinitrate ointment and anal cryothermal dilators only with 0.25 percent glycerin trinitrate ointment and only with anal cryothermal dilators in the treatment of chronic anal fissure: a two-year follow-up. Dis Colon Rectum. 2006 Dec;49(12):1822-30."
            }
        ], 
        "secondary_outcome": {
            "measure": "\u2022 Absolute change from baseline  in 24-hour average anal fissure pain scores assessed by the Wong-Baker FACES\u00ae and the Numerical Rating Scale for pain after each evening dose over days 1 through 4", 
            "safety_issue": "No", 
            "time_frame": "Day 5"
        }, 
        "source": "Aptalis Pharma", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Aptalis Pharma", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2013", 
        "study_design": "Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "August 2013"
    }
}